Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Oral Cancer | Research

FAM13A polymorphisms are associated with a specific susceptibility to clinical progression of oral cancer in alcohol drinkers

Authors: Ming-Ju Hsieh, Yu-Sheng Lo, Yun-Jung Tsai, Hsin-Yu Ho, Chia-Chieh Lin, Yi-Ching Chuang, Shu-Hui Lin, Mu-Kuan Chen

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Single nucleotide polymorphism (SNP) is a genetic variation that occurs when a single nucleotide base in the DNA sequence varies between individuals and is present in at least 1% of the population. Genetic variants in FAM13A are associated with different types of chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and lung cancer. However, there is little literature on the association of FAM13A genotypes with oral cancer. Therefore, this project will explore the correlation between the FAM13A genotype and the formation of oral cancer.

Methods

In this project, we will examine the presence of gene polymorphisms gene polymorphisms of rs1059122, rs3017895, rs3756050, and rs7657817 in the FAM13A gene exon, and combine the expression of these genes to try to clarify the impact of the FAM13A gene polymorphism on oral cancer. First, four loci (rs1059122, rs3017895, rs3756050, and rs7657817) of the FAM13A SNP were genotyped using TaqMan allelic discrimination.

Results

By estimating OR and AOR, FAM13A exhibited different genotypic variables in four SNPs that were not statistically significant between controls and patients with oral cancer. The results of the general analysis showed that different distributions of allelic types did not affect clinical stage, tumour size, lymph node invasion, distant metastasis, and pathological differentiation status. However, in the alcohol drinking group specifically, patients with the rs3017895 SNP G genotype had a 3.17-fold (95% CI, 1.102–9.116; p = 0.032) increase in the well differentiated state of cells compared to patients with the A allele.

Conclusions

Our results suggested that the SNP rs3017895 FAM13A could contribute to oral cancer. More sample studies are needed in the future to confirm our results and more functional studies are needed to investigate their relevant roles in the development of oral cancer.
Literature
1.
Lin NC, Hsien SI, Hsu JT, Chen MYC. Impact on patients with oral squamous cell carcinoma in different anatomical subsites: a single-center study in Taiwan. Sci Rep. 2021;11(1):15446.PubMedPubMedCentralCrossRef
2.
Li C, Chen X, Ren X, Chen JL, Chen H, Yu JJ, Ran QC, Kang S, Chen XM, Zhao ZJ. Identification of Hypoxia-Related Molecular Classification and Associated Gene Signature in Oral Squamous Cell Carcinoma. Front Oncol. 2021;11:709865.PubMedPubMedCentralCrossRef
3.
Taghavi N, Yazdi I. Prognostic factors of survival rate in oral squamous cell carcinoma: clinical, histologic, genetic and molecular concepts. Arch Iran Med. 2015;18(5):314–9.PubMed
4.
Bavle RM, Venugopal R, Konda P, Muniswamappa S, Makarla S. Molecular Classification of Oral Squamous Cell Carcinoma. J Clin Diagn Res. 2016;10(9):ZE18–21.PubMedPubMedCentral
5.
6.
Chung CM, Lee CH, Chen MK, Lee KW, Lan CE, Kwan AL, Tsai MH, Ko YC. Combined Genetic Biomarkers and Betel Quid Chewing for Identifying High-Risk Group for Oral Cancer Occurrence. Cancer Prev Res (Phila). 2017;10(6):355–62.PubMedCrossRef
7.
8.
9.
van Moorsel CHM. Trade-offs in aging lung diseases: a review on shared but opposite genetic risk variants in idiopathic pulmonary fibrosis, lung cancer and chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2018;24(3):309–17.PubMedPubMedCentralCrossRef
10.
Ziolkowska-Suchanek I, Mosor M, Gabryel P, Grabicki M, Zurawek M, Fichna M, Strauss E, Batura-Gabryel H, Dyszkiewicz W, Nowak J. Susceptibility loci in lung cancer and COPD: association of IREB2 and FAM13A with pulmonary diseases. Sci Rep. 2015;5:13502.PubMedPubMedCentralCrossRef
11.
Cohen M, Reichenstein M, Everts-van der Wind A, Heon-Lee J, Shani M, Lewin HA, Weller JI, Ron M, Seroussi E. Cloning and characterization of FAM13A1–a gene near a milk protein QTL on BTA6: evidence for population-wide linkage disequilibrium in Israeli Holsteins. Genomics. 2004;84(2):374–83.PubMedCrossRef
12.
Eisenhut F, Heim L, Trump S, Mittler S, Sopel N, Andreev K, Ferrazzi F, Ekici AB, Rieker R, Springel R, et al. FAM13A is associated with non-small cell lung cancer (NSCLC) progression and controls tumor cell proliferation and survival. Oncoimmunology. 2017;6(1):e1256526.PubMedCrossRef
13.
Hirano C, Ohshimo S, Horimasu Y, Iwamoto H, Fujitaka K, Hamada H, Hattori N, Shime N, Bonella F, Guzman J, et al. FAM13A polymorphism as a prognostic factor in patients with idiopathic pulmonary fibrosis. Respir Med. 2017;123:105–9.PubMedCrossRef
14.
Yu Y, Mao L, Lu X, Yuan W, Chen Y, Jiang L, Ding L, Sang L, Xu Z, Tian T, et al. Functional Variant in 3’UTR of FAM13A Is Potentially Associated with Susceptibility and Survival of Lung Squamous Carcinoma. DNA Cell Biol. 2019;38(11):1269–77.PubMedCrossRef
15.
Zhu J, Wang F, Feng X, Li B, Ma L, Zhang J. Family with sequence similarity 13 member A mediates TGF-beta1-induced EMT in small airway epithelium of patients with chronic obstructive pulmonary disease. Respir Res. 2021;22(1):192.PubMedPubMedCentralCrossRef
16.
Young RP, Hopkins RJ, Hay BA, Whittington CF, Epton MJ, Gamble GD. FAM13A locus in COPD is independently associated with lung cancer - evidence of a molecular genetic link between COPD and lung cancer. Appl Clin Genet. 2011;4:1–10.PubMed
17.
Zhang Y, Wang S, Wang C, Xiao J, Zhang S, Zhou H. High expression of FAM13A was associated with increasing the liver cirrhosis risk. Mol Genet Genomic Med. 2019;7(3):e543.PubMedPubMedCentralCrossRef
18.
Wei Y, Wang X, Zhang Z, Xie M, Li Y, Cao H, Zhao X. Role of Polymorphisms of FAM13A, PHLDB1, and CYP24A1 in Breast Cancer Risk. Curr Mol Med. 2019;19(8):579–88.PubMedCrossRef
19.
Lydiatt WM, Patel SG, O’Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, Loomis AM, Shah JP. Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(2):122–37.PubMedCrossRef
20.
Lu HJ, Chuang CY, Chen MK, Su CW, Yang WE, Yeh CM, Lai KM, Tang CH, Lin CW, Yang SF. The impact of ALDH7A1 variants in oral cancer development and prognosis. Aging (Albany NY). 2022;14(10):4556–71.PubMedCrossRef
21.
Mackay IM. Real-time PCR in the microbiology laboratory. Clin Microbiol Infect. 2004;10(3):190–212.PubMedCrossRef
22.
Hua KT, Liu YF, Hsu CL, Cheng TY, Yang CY, Chang JS, Lee WJ, Hsiao M, Juan HF, Chien MH, et al. 3’UTR polymorphisms of carbonic anhydrase IX determine the miR-34a targeting efficiency and prognosis of hepatocellular carcinoma. Sci Rep. 2017;7(1):4466.PubMedPubMedCentralCrossRef
23.
Goldman MJ, Craft B, Hastie M, Repecka K, McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675–8.PubMedPubMedCentralCrossRef
24.
Shieu MK, Ho HY, Lin SH, Lo YS, Lin CC, Chuang YC, et al. Association of KMT2C genetic variants with the clinicopathologic development of oral cancer. Int J Environ Res Public Health. 2022;19(7):3974–83.
25.
Wang EY, Chen MK, Hsieh MY, Kor CT, Liu YT. Relationship between preoperative nutritional status and clinical outcomes in patients with head and neck cancer. Nutrients. 2022;14(24):5331–44.
26.
Huang SH, O’Sullivan B. Overview of the 8th Edition TNM Classification for Head and Neck Cancer. Curr Treat Options Oncol. 2017;18(7):40.PubMedCrossRef
27.
28.
Srinivasan S, Clements JA, Batra J. Single nucleotide polymorphisms in clinics: Fantasy or reality for cancer? Crit Rev Clin Lab Sci. 2016;53(1):29–39.PubMedCrossRef
29.
Stadler ZK, Thom P, Robson ME, Weitzel JN, Kauff ND, Hurley KE, Devlin V, Gold B, Klein RJ, Offit K. Genome-wide association studies of cancer. J Clin Oncol. 2010;28(27):4255–67.PubMedPubMedCentralCrossRef
30.
Mbemi A, Khanna S, Njiki S, Yedjou CG, Tchounwou PB. Impact of gene-environment interactions on cancer development. Int J Environ Res Public Health. 2020;17(21):8089–103.
31.
Ram H, Sarkar J, Kumar H, Konwar R, Bhatt ML, Mohammad S. Oral cancer: risk factors and molecular pathogenesis. J Maxillofac Oral Surg. 2011;10(2):132–7.PubMedPubMedCentralCrossRef
32.
Jefferies S, Eeles R, Goldgar D, A’Hern R, Henk JM, Gore M. The role of genetic factors in predisposition to squamous cell cancer of the head and neck. Br J Cancer. 1999;79(5–6):865–7.PubMedPubMedCentralCrossRef
33.
Katiyar T, Yadav V, Maurya SS, Ruwali M, Singh M, Hasan F, Pandey R, Mehrotra D, Singh S, Mishra S, et al. Interaction of glutathione-s-transferase genotypes with environmental risk factors in determining susceptibility to head and neck cancer and treatment response and survival outcome. Environ Mol Mutagen. 2020;61(5):574–84.PubMedCrossRef
34.
Singh M, Shah PP, Singh AP, Ruwali M, Mathur N, Pant MC, Parmar D. Association of genetic polymorphisms in glutathione S-transferases and susceptibility to head and neck cancer. Mutat Res. 2008;638(1–2):184–94.PubMedCrossRef
35.
Liu L, Wu G, Xue F, Li Y, Shi J, Han J, Zhang X, Na Y, Zhang H, Tang X, et al. Functional CYP1A1 genetic variants, alone and in combination with smoking, contribute to development of head and neck cancers. Eur J Cancer. 2013;49(9):2143–51.PubMedCrossRef
36.
Edenberg HJ. The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants. Alcohol Res Health. 2007;30(1):5–13.PubMedPubMedCentral
37.
Brennan P, Lewis S, Hashibe M, Bell DA, Boffetta P, Bouchardy C, Caporaso N, Chen C, Coutelle C, Diehl SR, et al. Pooled analysis of alcohol dehydrogenase genotypes and head and neck cancer: a HuGE review. Am J Epidemiol. 2004;159(1):1–16.PubMedCrossRef
38.
Wang XJ, Li S, Fang J, Yan ZJ, Luo GC. LncRNA FAM13A-AS1 Promotes Renal Carcinoma Tumorigenesis Through Sponging miR-141-3p to Upregulate NEK6 Expression. Front Mol Biosci. 2022;9:738711.PubMedPubMedCentralCrossRef
39.
Qiu Z, He L, Yu F, Lv H, Zhou Y. LncRNA FAM13A-AS1 Regulates Proliferation and Apoptosis of Cervical Cancer Cells by Targeting miRNA-205-3p/DDI2 Axis. J Oncol. 2022;2022:8411919.PubMedPubMedCentralCrossRef
40.
41.
Turati F, Garavello W, Tramacere I, Bagnardi V, Rota M, Scotti L, Islami F, Corrao G, Boffetta P, La Vecchia C, et al. A meta-analysis of alcohol drinking and oral and pharyngeal cancers. Part 2: results by subsites. Oral Oncol. 2010;46(10):720–6.PubMedCrossRef
42.
Ko YC, Huang YL, Lee CH, Chen MJ, Lin LM, Tsai CC. Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med. 1995;24(10):450–3.PubMedCrossRef
43.
Huang CC, Hsiao JR, Lee WT, Lee YC, Ou CY, Chang CC, Lu YC, Huang JS, Wong TY, Chen KC, et al. Investigating the Association between Alcohol and Risk of Head and Neck Cancer in Taiwan. Sci Rep. 2017;7(1):9701.PubMedPubMedCentralCrossRef
44.
Cho MH, Boutaoui N, Klanderman BJ, Sylvia JS, Ziniti JP, Hersh CP, DeMeo DL, Hunninghake GM, Litonjua AA, Sparrow D, et al. Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nat Genet. 2010;42(3):200–2.PubMedPubMedCentralCrossRef
45.
Viswanathan H, Wilson JA. Alcohol–the neglected risk factor in head and neck cancer. Clin Otolaryngol Allied Sci. 2004;29(4):295–300.PubMedCrossRef
46.
Werbrouck J, De Ruyck K, Duprez F, Van Eijkeren M, Rietzschel E, Bekaert S, Vral A, De Neve W, Thierens H. Single-nucleotide polymorphisms in DNA double-strand break repair genes: association with head and neck cancer and interaction with tobacco use and alcohol consumption. Mutat Res. 2008;656(1–2):74–81.PubMedCrossRef
Metadata
Title
FAM13A polymorphisms are associated with a specific susceptibility to clinical progression of oral cancer in alcohol drinkers
Authors
Ming-Ju Hsieh
Yu-Sheng Lo
Yun-Jung Tsai
Hsin-Yu Ho
Chia-Chieh Lin
Yi-Ching Chuang
Shu-Hui Lin
Mu-Kuan Chen
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11052-5

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Early relapse is an adverse prognostic factor for survival outcomes in patients with oral cavity squamous cell carcinoma: results from a nationwide registry study

Research

Depletion of SOD2 enhances nasopharyngeal carcinoma cell radiosensitivity via ferroptosis induction modulated by DHODH inhibition

Research

Photon and Proton irradiation in Patient-derived, Three-Dimensional Soft Tissue Sarcoma Models

Research

MLXIPL promotes the migration, invasion, and glycolysis of hepatocellular carcinoma cells by phosphorylation of mTOR

Study Protocol

Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH study (WJOG 14720 L)

Research

Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits